Reassessing kinetin's effect on PINK1 and mitophagy

Area of Science:

• Mitochondrial biology
• Neurodegenerative disease research
• Protein kinase biochemistry

Background:

• Mitochondrial dysfunction is implicated in Parkinson disease pathogenesis.
• Mitophagy, the clearance of damaged mitochondria, is a therapeutic target for Parkinson disease.
• PINK1 (PTEN-induced kinase 1) initiates the mitophagy pathway.

Purpose of the Study:

• To elucidate the mechanism by which kinetin triphosphate (KTP) enhances PINK1 kinase activity.
• To investigate the interaction between KTP and the ATP binding pocket of PINK1.
• To re-evaluate the role of kinetin and its derivatives in mitophagy.

Main Methods:

• X-ray crystallography to determine nucleotide-bound PINK1 structures.
• Site-directed mutagenesis to alter the ATP binding pocket of PINK1.
• Cell-based assays to assess the effects of kinetin and KTP on mitophagy.

Main Results:

• Structural analysis showed KTP clashes with the native ATP binding pocket of PINK1.
• Mutagenesis of the ATP binding pocket enabled PINK1 to utilize KTP as a substrate.
• Mutations shifted PINK1's nucleotide preference from ATP to KTP.
• In-cell experiments confirmed that kinetin, a KTP precursor, does not function via direct PINK1 activation.

Conclusions:

• The previously proposed mechanism of KTP-mediated PINK1 activation is incorrect.
• PINK1 cannot directly use KTP due to steric hindrance in its ATP binding site.
• Kinetin and its derivatives likely promote mitophagy through an alternative, yet unidentified, pathway.